The study will be conducted in more than 130 patients. It is planned to screen men and women aged up to 65. The enrolled patients will be randomized in two treatment arms in a 1:1 ratio.
Botulinum toxin-A intramuscular injections are now the treatment of choice for glabellar lines resulting from hyperfunctional facial muscles. It has been shown to be more effective, convenient and less dangerous than other treatments.
In this trial, OCT will be responsible for different study-related activities, including project management, clinical monitoring, logistics, quality assurance and final report preparation.